A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer (NIAGARA).

  • Voskoboynik, Mark (Primary Chief Investigator (PCI))
  • Cross, Nikki (Project Manager)

Project: Research

Project Details

Effective start/end date6/02/1931/12/24


  • Medical Oncology
  • Bladder Cancer
  • Clinical Trial